CytomX(CTMX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - CytomX Therapeutics reported a confirmed overall response rate of 32% at a dose of 10 mg/kg and 20% at 8.6 mg/kg for Varseta-M, with a median progression-free survival (PFS) of 7.1 months and 6.8 months respectively [11][17] - The company noted an improvement in estimated PFS from 5.8 months in May 2025 to 6.8-7.1 months as of January 2026 [11][17] Business Line Data and Key Metrics Changes - Varseta-M is positioned as a first-in-class antibody-drug conjugate targeting EpCAM, specifically designed for colorectal cancer (CRC) [4][6] - The ongoing phase 1 study has enrolled a total of 93 patients, with a focus on dose optimization for the top two doses of 8.6 and 10 mg/kg [10][14] Market Data and Key Metrics Changes - Colorectal cancer is projected to see an increase in diagnoses from 1.9 million patients per year to over 3 million by 2040, representing a significant market opportunity [5][6] - The third-line setting alone is projected to have 45,000 addressable patients in the U.S. by 2040, indicating a multibillion-dollar market potential [6][30] Company Strategy and Development Direction - The company aims to aggressively advance Varseta-M into its first registrational study, targeting late-line CRC, with plans to expand into earlier lines of therapy and other EpCAM-positive tumors [12][30] - CytomX is focused on transforming CRC treatment paradigms and believes Varseta-M can replace existing therapies like Irinotecan [30][31] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the drug's performance and its potential to significantly impact patient outcomes in CRC, emphasizing the importance of the ongoing clinical data [29][30] - The company is committed to refining its prophylactic strategies to manage treatment-related adverse events, particularly diarrhea, which has been a significant concern [19][20] Other Important Information - The safety profile of Varseta-M has shown no evidence of classic EpCAM toxicities, and the company is implementing dual prophylaxis strategies to manage diarrhea effectively [11][19] - The pharmacokinetics of Varseta-M indicate a mean half-life of 6-8 days, supporting the dosing strategy based on adjusted ideal body weight [25] Q&A Session Summary Question: What is the anticipated size of the pivotal trial? - Management indicated that the pivotal study size is still under consideration, but they are encouraged by the activity levels observed in late-line CRC [35][38] Question: What are the potential indications beyond CRC for Varseta-M? - Management highlighted the potential for Varseta-M in other solid tumors, including gastric, pancreatic, lung, ovarian, and certain breast cancers, as EpCAM is expressed in many of these cancers [39][40] Question: How will the prophylactic protocol be implemented in real-world settings? - Management noted that the dual prophylactic regimen of loperamide and budesonide is expected to be well-adhered to in real-world settings, especially since both medications are oral [46][70] Question: Will PFS be the sole primary endpoint in the pivotal study? - Management confirmed that overall survival (OS) will be the primary endpoint, although they are considering all options to accelerate the development of Varseta-M [48][49] Question: How does Varseta-M compare to other ADCs in development? - Management emphasized that Varseta-M is a first-in-class ADC targeting EpCAM and believes it may be the best-in-class ADC for CRC based on current data [53][54]